Thymus Cancer

Thymome : tout savoir sur le #cancer du thymus #Tumeur #Symptômes #Diagnostic #Traitements @BenjaminBesseMD @GustaveRoussy #Métastase @Institut_cancer #radiothérapie #RadOnc | #hcsmeufr @scoopit https://t.co/Sxo3CmVejC (@radiotherapiefr)

Thymome : tout savoir sur le #cancer du thymus #Tumeur #Symptômes #Diagnostic #Traitements @BenjaminBesseMD @GustaveRoussy #Métastase @Institut_cancer #radiothérapie #RadOnc | #hcsmeufr @scoopit https://t.co/2oxtGmQLN0 (@Accuray_Fr)

"Small cell, thymoma, and now mesothelioma... all on day 1. What a time to be alive!" - @kaushalpar discussing cfDNA detection of chromosomal junctions for mesothelioma at #DAVAHawaiiLung. Part of an excellent panel overall! (@KE_Gallaway)

Nice session at #ESTS2023 on upcoming @IASLC 9th edition staging for lung cancer, thymic malignancies, and mesothelioma. Changes coming. More to hear at #WCLC2023! (@BrendonStilesMD)

@ArdeshirFatemeh giving us insights to predict disease progression in thymoma! Our fellows @IUHemOnc at @IUCancerCenter are amazing! #ASCO23 #ResearchCuresCancer (@JenSchwartzIUSM)

Hope you had the chance to see our amazing fellow @ArdeshirFatemeh and her poster on thymoma and predicting progression! @IUHemOnc @IUSMDeptMed @IUMedSchool (@JenSchwartzIUSM)

Learn from @IUHemOnc fellow, Fatemah Ardeshir-Larijani, MD, (@ArdeshirFatemeh) about circulating tumor DNA analysis for metastatic thymic tumors during this poster session. #ResearchCuresCancer #ASCO23 🕘: 9:00 a.m. EDT/8:00 a.m. CDT 📍: Hall A @RManiarMD @ashiq_masood (@IUCancerCenter)

Quite incisive question there😉🙏 True, in practice it means more like no recurrence after 5 years (though longer for thymoma, breast ca, prostate ca), yet what does one do when there is a cytostatic drug in there for 3 years? 🧐 (@HenningWillers)

Shoutout to @ConquerCancerFd Merit Award recipients @SamyuktaMD (@MSKCancerCenter @ThymeCares) & Jeffrey Shevach (@PennCancer), and to Xavier Orcutt for leading an awesome (IMO) analysis of #MachineLearning to evaluate #clinicaltrials generalizability (@aaronbcohen @tjroycemd) (@ravi_b_parikh)

Ugh, having lost my Dad to an aggressive thymic malignancy my condolences are tinged with empathy I am very sorry — this disease can touch literally anyone & I wonder if our wounded grief actually fuels oncologists’ passion to improve cancer care Here’s to better, longer lives (@marklewismd)

A very personal tweet; today I lost my kind, beautiful, loving cousin, my age, to a thymoma, a diagnosis made months after symptoms were labeled as depression in a war-torn country. Do not underestimate how lucky we are with the access to healthcare that we have. #unfair (@MyriamChalabi)

American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma. https://t.co/5doAT5yDKI (@radioncoluis)

American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma | Cardiothoracic Surgery | JAMA Oncology | JAMA Network https://t.co/hUM2HHw3ac (@LujanPomponio)

Happy to announce the publication of our ARS thymic carcinoma manuscript in JAMA Oncology on line today. ARS AUC thoracic committee made another significant contribution to oncology community. See the link: https://t.co/hb0SDGCuhV (@JoeChangMD)

How should we deliver #radiotherapy for thymic cancer in the UK? Work presented at #ESTRO23 shows disparate Thymic carcinoma care. Real need to establish a Central UK Thymic Ca MDT (@gerryhanna)

Launching Thymic Malignancy Awareness Month with a webinar "Clinical Trials for Thymic Epithelial Tumors" We've had insightful presentations on innovative clinical trials for TETs! Dr. Meredith McAdams @dwightowenmd @ChrisNabelMD Dr. Annemarie Shepherd @Itmig_society (@chulkimMD)

3/4 8⃣ Stage III Thymoma @nicogirardcurie @DrSanjayPopat 9⃣ CM816,CONTACT-01,EMPower-Lung-03, RESILIENT update @nicogirardcurie @charlesrudin @JoelNealMD 🔟 Debate on duration of adj TKI @HelenaYu923 @Alfdoc2 1⃣1⃣ Debate on adj chemo in EGFR+ @LauraMezquitaMD @BenjaminBesseMD (@g_mountzios)

Molecularly matched therapy (MMT) was given in 2009 :) This is my first MMT case-thymic carcinoma with C-KIT mutation . (@UmutDisel)

Avelumab/axitinib in B3 thymoma & thymic carcinoma (CAVEATT) N=32 (thymic carcinoma majority) ORR=34% Similar PFS between between PD-L1 high vs. PD-L1 low/negative is notable Incidence of serious irAEs=12% (similar to PD-1 monoTx) @TheLancetOncol https://t.co/LQL8ueEWJQ (@chulkimMD)

The purpose of this #meta-analysis is to characterize the association🔀 between PD-L1 expression and different stages of #thymoma 🆓🔗https://t.co/OJz3i5VnZh #thymiccarcinoma #rarecancer @Dr_Ivanoncologo @AbhijitSurgPath @smlungpathguy #pathology (@TumoriJ)

📣 Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in #ThymicEpithelialTumors 👨‍⚕️👩‍⚕️ @AnjaRodenMD @AMansfieldMD Read here 👉 https://t.co/xCecYhcVRD #ThoracicOncology #Imaging (@FrontOncology)

#WCLC21 Dr. Hyun Ae Jung with results from phase II study of palbociclib (CDK4/6) in recurrent thymic epithelial tumors. RR 14% with mPFS 11m - encouraging. Myelosuppressive (>40% G3 neutropenia). Salvage therapy for TET remains an unmet need - would like to see larger studies. (@StephenVLiu)

Targeting mTOR and CDK4/6 in #thymictumors ⁦@SukiPaddaMD⁩ thymoma versus thymic carcinoma diagnosis in autoimmune syndromes ⁦@gotoPER⁩ #ilc2021 with cochairs ⁦@HwakeleeMD⁩ ⁦@drgandara⁩ ⁦@DrRoyHerbstYale⁩ ⁦@CedarsSinai⁩ (@donnashort)

My DDs in this biopsy are 1. Thymoma type B3 2. Follicular dendritic cell sarcoma (CD5, Cytokeratin, TdT, Clusterin, CD21 and CD23) (@Venkateshgilly2)

There is a clear niche for IO in thymoma beyond TC (⬆️ rate of PDL1 expression in TETs)? 3.3% of AID in TC (OR=0.11, [0,042-0,318]) v 38% in B3 after pathological central review ➡️(1899P)✅. #ESMO20 @benjaminbesse @IFCT @GustaveRoussy @institut_curie @hopital_necker @OncoAlert (@JcbenitezMD)

Phase I MGD019 (bispecific PD-L1+CTLA4 DART) in solid tumors (N=18) with 4 responses [13%: mCRC and thymoma (confirmed), and a CR in prostate #cancer]: #clinicaltrials #cancerresearch #cancer #ESMO20 #immunotherapy @myESMO @VUMC_Cancer @VUMChealth @MacroGenics #crcsm @OncoAlert (@CathyEngMD)

Favor Thymoma IHC: CK Ae1/Ae3, LCA & CD117 (@MarkEvanUy1)